Detectable Serum Levels of Tumor Necrosis Factor Alpha May Predict Early Mortality in Elderly Institutionalized Patients

Journal of the American Geriatrics Society

Volumn 39, Issue 9, 1991, Pages 891-894

  Mooradian, Arshag D ^a   Reed, Richard L ^a   Osterweil, Dan ^b   Scuderi, Philip ^c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Los Angeles Jewish Home for the Aging   (United States)

^c BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NURSING HOME; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; CAUSE OF DEATH; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HOMES FOR THE AGED; HUMAN; INSTITUTIONALIZATION; INTERLEUKIN-1; LOS ANGELES; MALE; MORTALITY; NURSING HOMES; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR;

EID: 0026005830     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1991.tb04456.x     Document Type: Article

References (30)

1. Regulation of food intake and hepatic protein metabolism by recombinant‐derived monokines
2. Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation
3. Effects of tumor necrosis factor α, cachectin, on thyroid hormone metabolism in mice
4. Impairment of hypothalamic‐pituitary‐thyroid function in rats treated with human recombinant tumor necrosis factor α (cachectin)
5. Shock and tissue injury induced by recombinant human cachectin
6. Cachectin: More than a tumor necrosis factor
7. Activation of coagulation after administration of tumor necrosis factor to normal subjects
8. Acute in vivo effects of human recombinant tumor necrosis factor
9. Lack of an association between the presence of tumor necrosis factor or interleukin‐1 alpha in the blood and weight loss among elderly patients
10. Radioimmunoassay of tumor necrosis factor in serum
11. 3) is associated with increased concentrations of tumor necrosis factor
12. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance
13. Influence of blood‐collecting systems on concentrations of tumor necrosis factor in serum and plasma
14. Raised serum levels of tumor necrosis factor in parasitic infections
15. Suppression of human leukocyte tumor necrosis factor secretion by the serine protease inhibitor p‐toluenesulfonyl‐L‐arginine methyl ester (TAME)
16. Nonparametric estimation from incomplete observations
17. Statistical aspects of the analysis of data from retrospective studies of disease
18. Tumor necrosis factor and interleukin‐1 in the serum of children with severe infectious purpura
19. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease
20. Grip strength, mental performance and nutritional status as indicators of mortality risk among female geriatric patients
21. Antecedents of death in the men of a Veterans Administration nursing home
22. Relation of serum albumin concentration to death rate in nursing home men
23. Prognostic significance of serum cholesterol in nursing home men
24. Circulating interleukin‐1 and tumor necrosis factor‐alpha (cachectin) in inflammation
25. Cytokine appearance in human endotoxemia and primate bacteremia
26. Detection of circulating tumor necrosis factor after endotoxin administration
27. Evidence for tumor necrosis factor/cachectin production in cancer
28. Serum levels of tumor necrosis factor and interleukin‐1 alpha in diabetic patients
29. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure